Core Viewpoint - The company has announced the completion of the deregistration of its wholly-owned subsidiary, Dalian Gai Shi Biotechnology Co., Ltd., as part of its strategy to optimize internal management and improve operational efficiency [1] Company Summary - Dalian Gai Shi Biotechnology Co., Ltd. was established on March 12, 2013, with a registered capital of 1 million RMB [1] - The subsidiary's registered address was located in Lushunkou District, Dalian, Liaoning Province [1] - The business scope included production and R&D of materials required for edible and medicinal fungi cultivation, manufacturing and sales of health foods, fermented products, beverages, frozen foods, canned foods, and soybean products, as well as processing and sales of aquatic products, vegetables, fruits, and nuts [1] Strategic Implications - The deregistration of the subsidiary aligns with the company's operational development needs and is aimed at enhancing overall efficiency [1]

Core Viewpoint - Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd. plans to deregister its subsidiary Nanjing Nuohexin Pharmaceutical Technology Co., Ltd. to optimize internal management and reduce operational costs [1][2] Group 1: Company Overview - The company is proposing to deregister its controlling subsidiary Nanjing Nuohexin, which is considered a related transaction but does not constitute a major asset restructuring [1][2] - Zhao Lingyang, who held various positions in the company from January 2019 to September 2024 and owns 18% of Nuohexin, is identified as a related party [2][3] Group 2: Financial Information - Nuohexin's total assets as of December 31, 2024, were approximately 10.14 million yuan, up from about 8.74 million yuan in 2023, indicating a growth of approximately 15.98% [4] - The total liabilities of Nuohexin increased from approximately 872,784.84 yuan in 2023 to about 9.19 million yuan in 2024, reflecting a significant rise [4] - Nuohexin reported a total revenue of approximately 7.60 million yuan in 2024, with a net loss of about 6.92 million yuan, compared to a net loss of approximately 3.23 million yuan in 2023 [5] Group 3: Reasons for Deregistration - The decision to deregister Nuohexin is based on the company's development plan and the operational status of the subsidiary, aiming to streamline management and enhance operational efficiency [2][5] - After deregistration, the core business and employees of Nuohexin will be managed by its controlling shareholder, ensuring a smooth transition and protection of employee rights [5] Group 4: Impact of Deregistration - The proposed deregistration is not expected to have a significant impact on the overall business development and profitability of the company, although it will change the scope of the consolidated financial statements [5]